Precision Biosciences (DTIL) Current Assets (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Current Assets data on file, last reported at $108.7 million in Q1 2026.

• On a quarterly basis, Current Assets rose 32.39% year-over-year to $108.7 million in Q1 2026; TTM through Mar 2026 was $108.7 million, a 32.39% increase from a year earlier, with the FY2025 full-year figure at $118.7 million, up 25.0% from the prior year.
• Current Assets for Q1 2026 stood at $108.7 million, down from $118.7 million in the prior quarter.
• Over the last five years, Current Assets for DTIL reached as high as $247.7 million in Q2 2022 and fell as low as $51.7 million in Q3 2025.
• Historically, Current Assets has averaged $138.1 million across 5 years, with a median of $136.4 million in 2023.
• Across the five-year window, Current Assets sank 53.22% in 2025 and surged 32.39% in 2026, its largest moves.
• Year by year, Current Assets stood at $199.1 million in 2022, then tumbled by 31.51% to $136.4 million in 2023, then plunged by 30.34% to $95.0 million in 2024, then gained by 25.0% to $118.7 million in 2025, then declined by 8.46% to $108.7 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $108.7 million in Q1 2026, $118.7 million in Q4 2025, and $51.7 million in Q3 2025.